Haina Pharmaceuticals
Pioneering breakthroughs in drug research and development since 2001, with state-of-the-art R&D centers spanning over 5,000 square meters in Nanjing City.
Pioneering breakthroughs in drug research and development since 2001, with state-of-the-art R&D centers spanning over 5,000 square meters in Nanjing City.
Haina Pharmaceuticals is a leading pharmaceutical company that has been pioneering breakthroughs in drug research and development since 2001. The company, based in Nanjing City, China, has been making significant strides in the healthcare and pharmaceutical industries. Haina Pharmaceuticals is dedicated to biological sample testing, drug registration, and pharmaceutical research and development. The company operates two state-of-the-art R&D centers spanning over 5,000 square meters in Gulou District and Jiangbei New District, Nanjing. These facilities have witnessed a substantial investment of over 400 million yuan and are fully equipped with comprehensive drug research and development equipment and a robust management system. Moreover, the recent Series B investment at 16 August 2022 has garnered significant attention, with CICC and Sunland Capital contributing to fuel the company's growth and innovation. Haina Pharmaceuticals stands out as a promising player in the pharmaceutical industry, with its dedication to research, development, and cutting-edge facilities positioning it for future success in the global market.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series B | Unknown | 2 |
|
16 Aug 2022 |
No recent news or press coverage available for Haina Pharmaceuticals.
-Limited-logo.jpg){kind=logo}
We care about your data, and we'd love to use cookies make your experience better.